After an initial AI software licensing deal between Eli Lilly and Insilico Medicine three years ago, the companies are deepening their ties once again with a drug discovery and development collabor | ...

Excellergy has been snapped up by the Swiss pharma only five months after emerging with $70 million in funds. The Palo Alto, ...

After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical ...

With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...

Incubate Founder and Executive Director John Stanford spent a busy day on Capitol Hill this week making the case that the ...

Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive ...

China’s BrightGene has served up a slice of early-stage data to remind everyone it has a horse in the oral obesity race.  | ...

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, ...

The human eye is like an immunological fortress, with its ability to exclude unwanted intruders a boon when preventing ...

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...